Scribe Therapeutics
@scribetx.bsky.social
We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️🩹
Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...
#HeartDisease #OurHearts #HeartMonth
Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...
#HeartDisease #OurHearts #HeartMonth
February 7, 2026 at 12:28 AM
We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️🩹
Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...
#HeartDisease #OurHearts #HeartMonth
Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...
#HeartDisease #OurHearts #HeartMonth
💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention.
Links ⬇️
Links ⬇️
February 4, 2026 at 8:28 PM
💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention.
Links ⬇️
Links ⬇️
How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions?
Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧
Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧
January 30, 2026 at 6:00 PM
How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions?
Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧
Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧
As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease.
STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics.
More in @endpts.com 👇
STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics.
More in @endpts.com 👇
January 27, 2026 at 6:03 PM
As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease.
STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics.
More in @endpts.com 👇
STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics.
More in @endpts.com 👇
Another successful JPM is in the books 📕
From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.
From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.
January 23, 2026 at 6:11 PM
Another successful JPM is in the books 📕
From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.
From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.
We're pleased to announce:
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
January 20, 2026 at 1:13 PM
We're pleased to announce:
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
Happening TODAY at #JPM2026!
Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).
#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).
#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD
January 14, 2026 at 3:03 PM
Happening TODAY at #JPM2026!
Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).
#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).
#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Kick off JPM Week with us this Sunday!
Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more.
Details below 🧬👇
Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more.
Details below 🧬👇
January 9, 2026 at 5:14 PM
Kick off JPM Week with us this Sunday!
Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more.
Details below 🧬👇
Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more.
Details below 🧬👇
Coming up next week at #JPM2026:
Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!
Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!
Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD
January 7, 2026 at 7:34 PM
Coming up next week at #JPM2026:
Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!
Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!
Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Wishing everyone a Happy New Year!
January 1, 2026 at 7:26 PM
Wishing everyone a Happy New Year!
Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease.
Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇
singularityhub.com/2025/11/27/c...
Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇
singularityhub.com/2025/11/27/c...
CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results
A range of CRISPR gene therapies are taking aim at chronically high cholesterol, reducing the risk of heart disease.
singularityhub.com
December 23, 2025 at 6:00 PM
Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease.
Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇
singularityhub.com/2025/11/27/c...
Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇
singularityhub.com/2025/11/27/c...
ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease.
Article by @megadarren.bsky.social.
Article by @megadarren.bsky.social.
Scribe eyes clinic after CRISPR candidates lower lipids in animals
Genetic-medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three programs, all of which were able to reduce cardiovascular risk factors in | ...
www.fiercebiotech.com
December 19, 2025 at 5:04 PM
ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease.
Article by @megadarren.bsky.social.
Article by @megadarren.bsky.social.
Could a single treatment lower heart disease risk by up to 90%?
At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.
At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.
December 17, 2025 at 7:01 PM
Could a single treatment lower heart disease risk by up to 90%?
At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.
At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.
Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference.
Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.
#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.
#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD
December 15, 2025 at 2:07 PM
Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference.
Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.
#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.
#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD
Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies.
Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...
Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...
Can AI take the guesswork out of CRISPR?
New AI tools promise to speed up and simplify CRISPR experiments, but their real-world impact is still being tested.
www.drugdiscoverynews.com
December 4, 2025 at 6:31 PM
Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies.
Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...
Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...
This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide.
Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!
Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!
🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF!
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
December 1, 2025 at 6:03 PM
This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide.
Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!
Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!
As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful.
Happy Thanksgiving! 🦃
Happy Thanksgiving! 🦃
November 26, 2025 at 8:34 PM
As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful.
Happy Thanksgiving! 🦃
Happy Thanksgiving! 🦃
We’re excited to be featured in @longevitytech.bsky.social, where @mrdannysullivan.bsky.social sits down with our CEO @benjaminloakes.bsky.social to discuss how next-gen CRISPR therapies could extend lifespans by revolutionizing the treatment paradigm for CVD.
Read the full piece: bit.ly/4riTDZn
Read the full piece: bit.ly/4riTDZn
Can genetic medicine solve cardiovascular disease?
Scribe Therapeutics CEO on how CRISPR technologies are ready to move beyond rare diseases and take on the world’s biggest killers.
www.longevity.technology
November 24, 2025 at 6:57 PM
We’re excited to be featured in @longevitytech.bsky.social, where @mrdannysullivan.bsky.social sits down with our CEO @benjaminloakes.bsky.social to discuss how next-gen CRISPR therapies could extend lifespans by revolutionizing the treatment paradigm for CVD.
Read the full piece: bit.ly/4riTDZn
Read the full piece: bit.ly/4riTDZn
📅 Join today's Fierce Biotech Cell & Gene Turning Point event!
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
November 20, 2025 at 2:59 PM
📅 Join today's Fierce Biotech Cell & Gene Turning Point event!
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD.
Register for free now: www.fiercecellandgene.com
We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
November 17, 2025 at 6:53 PM
We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...
Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20.
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
November 11, 2025 at 6:04 PM
Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20.
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease.
Register for free here: www.fiercecellandgene.com
#AHA25 Scientific Sessions are underway!
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
November 7, 2025 at 6:33 PM
#AHA25 Scientific Sessions are underway!
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇
@ahascience.bsky.social
🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF!
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
November 5, 2025 at 8:31 PM
🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF!
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.
📣 #AHA25 is almost here! We’re headed to New Orleans to share the latest on our pipeline of #CRISPR genome editing & epigenetic silencing therapies for cardiometabolic disease.
Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇
Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇
November 3, 2025 at 6:07 PM
When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃
November 1, 2025 at 12:21 AM
When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃